Patents by Inventor Kalpana Shah

Kalpana Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11098119
    Abstract: The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”). The present invention also is directed to such diabodies that additionally comprise an immunoglobulin Fc Domain (“bi-specific Fc diabodies and bi-specific, tetra-valent, Fc diabodies”).
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 24, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Scott Koenig
  • Patent number: 11072653
    Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: July 27, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210206851
    Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Application
    Filed: January 12, 2021
    Publication date: July 8, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210130470
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 6, 2021
    Inventors: Leslie S. JOHNSON, Gurunadh Reddy CHICHILI, Kalpana SHAH, Ross LA MOTTE-MOHS, Paul A. Moore, Ezio Bonvini, Scott KOENIG
  • Patent number: 10954301
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: March 23, 2021
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Patent number: 10858430
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 8, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Publication number: 20200231675
    Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 23, 2020
    Applicant: MACROGENICS, INC
    Inventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20200207850
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Leslie S. JOHNSON, Ling HUANG, Gurunadh Reddy CHICHILI, Kalpana SHAH, Chia-Ying Kao LAM, Stephen James BURKE, Liqin LIU, Paul A. MOORE, Ezio BONVINI, Bhaswati BARAT
  • Publication number: 20200199223
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Ezio BONVINI, Paul A. MOORE, Jonathan C. LI, Leslie S. JOHNSON, Kalpana SHAH
  • Patent number: 10647768
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 12, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
  • Patent number: 10633440
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 28, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Ezio Bonvini, Paul A. Moore, Jonathan C. Li, Leslie S. Johnson, Kalpana Shah
  • Patent number: 10577422
    Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 3, 2020
    Assignee: Macrogenics, Inc.
    Inventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Patent number: 10501552
    Abstract: The present invention is directed to multivalent DR5-Binding Molecules that comprise Binding Domain(s) of anti-DR5 antibodies, and particularly Binding Domain(s) of anti-human DR5 antibodies. The DR5-Binding Molecules of the present invention include bivalent and tetravalent molecules having two, three or four DR5-Binding Domains each capable of binding human DR5. In particular, the present invention is directed to multivalent DR5-Binding Molecules that comprise diabodies, and more particularly, diabodies that comprise a covalently bonded complex of two or more polypeptide chains. The invention particularly pertains to such multivalent DR5-Binding Molecules that comprise of the anti-DR5 antibodies DR5 mAb 1 and/or DR5 mAb 2, and/or humanized and chimeric versions of such antibodies.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: December 10, 2019
    Assignee: MacroGenics, Inc.
    Inventors: Paul A. Moore, Leslie S. Johnson, Jonathan C. Li, Kalpana Shah
  • Publication number: 20190270813
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
    Type: Application
    Filed: May 15, 2019
    Publication date: September 5, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Paul A. Moore, Wei Chen
  • Patent number: 10344092
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: July 9, 2019
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Paul A. Moore, Wei Chen
  • Publication number: 20190169292
    Abstract: The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”). The present invention also is directed to such diabodies that additionally comprise an immunoglobulin Fc Domain (“bi-specific Fc diabodies and bi-specific, tetra-valent, Fc diabodies”).
    Type: Application
    Filed: November 13, 2018
    Publication date: June 6, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Scott Koenig
  • Publication number: 20190161548
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Application
    Filed: December 12, 2016
    Publication date: May 30, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20190127467
    Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.
    Type: Application
    Filed: July 28, 2016
    Publication date: May 2, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20190085075
    Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Application
    Filed: June 7, 2016
    Publication date: March 21, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20190002563
    Abstract: The present invention is directed to B7-H3×CD3 bispecific monovalent diabodies, and particularly, to B7-H3×CD3 bispecific monovalent Fc diabodies, that are capable of simultaneous binding to B7-H3 and CD3. The invention is also directed to pharmaceutical compositions that contain such bispecific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.
    Type: Application
    Filed: August 12, 2016
    Publication date: January 3, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Ling Huang, Kalpana Shah, Ralph Alderson, Gurunadh Reddy Chichili